Clinical Trial

UCAR T-cell Therapy Targeting CD19/BCMA in Relapsed/Refractory Autoimmune Hemolytic Anemia

Name: UCAR T-cell Therapy Targeting CD19/BCMA in Relapsed/Refractory Autoimmune Hemolytic Anemia — clinical trial record (NCT07530380)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Early Phase 1

View on ClinicalTrials.gov →

Summary

This is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in AIHA who have failed ≥ 3 lines of therapy

Trial Details

NCT Number	NCT07530380
Lead Sponsor	The Second Hospital of Anhui Medical University
Conditions	AIHA - Warm Autoimmune Hemolytic Anemia, UCART
Enrollment	15 participants
Start Date	2026-04
Primary Completion	2029-12-31 (estimated)
Study Completion	2030-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-04-15